|
A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma
|
|
U26-139-1
|
|
A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma
|
|
Dr. Swarup Kumar
|
|
The purpose of this study is to compare the effects of the investigational drug, called JNJ-79635322, with the BCMAxCD3 bispecific antibody, called Teclistamab, after at least 3 prior lines of therapy in patients with multiple myeloma.
|
Cancer - Multiple Myeloma
|
|
|
Check with study contact
|
|
Kristen Grandonico Telephone: 860-679-6580. Email: grandonico@uchc.edu
|
|
Enrolling/recruiting.
|
|
|